Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
Radiation therapy is a cornerstone in the treatment of many cancers, but its efficacy can be limited by the inherent resistance of certain cancer cells. Identifying agents that can sensitize these cells to radiation is a critical area of research. NINGBO INNO PHARMCHEM CO.,LTD. is proud to supply compounds like AZD2014 that play a significant role in these investigations. AZD2014, a potent dual inhibitor of mTORC1 and mTORC2, has emerged as a promising candidate for enhancing cancer cell radiosensitivity.
The mTOR pathway is intimately involved in cellular processes that influence a cell's response to various stressors, including ionizing radiation. By inhibiting both mTORC1 and mTORC2, AZD2014 can modulate cellular signaling cascades that govern cell survival and DNA repair mechanisms. Studies have specifically highlighted AZD2014's ability to increase the susceptibility of glioblastoma stem-like cells (GSCs) to irradiation. This effect has been demonstrated both in vitro and in vivo, indicating a significant therapeutic potential for improving outcomes in brain cancer patients.
Researchers have found that pre-treating GSCs with AZD2014 prior to irradiation leads to a marked decrease in clonogenic survival. This means that fewer cancer cells are able to form colonies after the combined treatment, suggesting that AZD2014 makes the cells more vulnerable to radiation-induced damage. The precise mechanisms are still being explored, but it is believed that AZD2014 interferes with the cellular machinery that allows cancer cells to withstand and recover from radiation exposure. This makes AZD2014 a valuable tool for understanding and improving radiation oncology strategies.
The implications of this finding are substantial. For patients with glioblastoma, a particularly aggressive form of brain cancer, any enhancement in treatment efficacy can translate to better prognoses. The ability of AZD2014 to sensitize these notoriously resistant cells to radiation offers a new avenue for therapeutic development. This focus on specific cancer types and treatment modalities highlights the nuanced application of targeted inhibitors. Companies like NINGBO INNO PHARMCHEM CO.,LTD. facilitate this progress by ensuring the availability of high-purity AZD2014 for leading research institutions.
As research continues, the role of dual mTOR inhibitors like AZD2014 in combination with radiation therapy is expected to grow. Understanding how to best utilize such compounds, including their purchase for experimental use, is key to advancing cancer care. NINGBO INNO PHARMCHEM CO.,LTD. remains committed to supporting the scientific community by providing the critical chemical building blocks needed for groundbreaking discoveries in cancer treatment.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
